cfdna extraction  (Qiagen)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 89
    Name:
    QIAseq cfDNA All in One T Kit
    Description:
    For conversion of cfDNA from plasma to NGS library for any liquid biopsy samples Kit contents For 24 reactions on Ion Torrent sequencers Includes QIAamp Mini Columns tubes reagents and buffers for cfDNA extraction for NGS enzyme and buffer master mix for cfDNA library prep Ion Torrent Adapter Plate 24 plex Ion Torrent Library Amplification Primer and PCR Master Mix Benefits Optimal conversion of cfDNA at every step from plasma to NGS library through highly efficient ligation chemistry Go directly from eluant to library prep without quantification using a protocol supporting the widest range of cfDNA input 1 100ng Generate PCR free libraries from 10 ng of cfDNA Minimize PCR bias by the use of high fidelity amplification reagents Reduce cross contamination risk with pre dispensed plate based adapters for up to 96 samples NGS ru
    Catalog Number:
    180043
    Price:
    1222
    Category:
    QIAseq cfDNA All in One Kits
    Buy from Supplier


    Structured Review

    Qiagen cfdna extraction
    QIAseq cfDNA All in One T Kit
    For conversion of cfDNA from plasma to NGS library for any liquid biopsy samples Kit contents For 24 reactions on Ion Torrent sequencers Includes QIAamp Mini Columns tubes reagents and buffers for cfDNA extraction for NGS enzyme and buffer master mix for cfDNA library prep Ion Torrent Adapter Plate 24 plex Ion Torrent Library Amplification Primer and PCR Master Mix Benefits Optimal conversion of cfDNA at every step from plasma to NGS library through highly efficient ligation chemistry Go directly from eluant to library prep without quantification using a protocol supporting the widest range of cfDNA input 1 100ng Generate PCR free libraries from 10 ng of cfDNA Minimize PCR bias by the use of high fidelity amplification reagents Reduce cross contamination risk with pre dispensed plate based adapters for up to 96 samples NGS ru
    https://www.bioz.com/result/cfdna extraction/product/Qiagen
    Average 89 stars, based on 8 article reviews
    Price from $9.99 to $1999.99
    cfdna extraction - by Bioz Stars, 2020-09
    89/100 stars

    Images

    1) Product Images from "Utility of Circulating Tumor DNA for Detection and Monitoring of Endometrial Cancer Recurrence and Progression"

    Article Title: Utility of Circulating Tumor DNA for Detection and Monitoring of Endometrial Cancer Recurrence and Progression

    Journal: Cancers

    doi: 10.3390/cancers12082231

    Multiregional sampling from patient 5, alongside the respective variant allele frequencies of the major driver mutation, TP53 p.Y220C, identified in the primary tumor sample (located in the endometrium), local metastatic lesion (located in the ovary) and the distal metastatic lesion (located in the omentum). The levels of cell-free DNA (cfDNA) and ctDNA in pre-treatment and post-treatment plasma samples are shown in the accompanying left-hand graph, clearly demonstrating a rise in ctDNA levels 3 months prior to radiological relapse (right-hand). * samples analyzed exclusively by digital droplet PCR (ddPCR). Grey shaded area indicates treatment with carboplatin and paclitaxel. PR = partial response; RP = radiological progression.
    Figure Legend Snippet: Multiregional sampling from patient 5, alongside the respective variant allele frequencies of the major driver mutation, TP53 p.Y220C, identified in the primary tumor sample (located in the endometrium), local metastatic lesion (located in the ovary) and the distal metastatic lesion (located in the omentum). The levels of cell-free DNA (cfDNA) and ctDNA in pre-treatment and post-treatment plasma samples are shown in the accompanying left-hand graph, clearly demonstrating a rise in ctDNA levels 3 months prior to radiological relapse (right-hand). * samples analyzed exclusively by digital droplet PCR (ddPCR). Grey shaded area indicates treatment with carboplatin and paclitaxel. PR = partial response; RP = radiological progression.

    Techniques Used: Sampling, Variant Assay, Mutagenesis, Polymerase Chain Reaction

    2) Product Images from "Utility of Circulating Tumor DNA for Detection and Monitoring of Endometrial Cancer Recurrence and Progression"

    Article Title: Utility of Circulating Tumor DNA for Detection and Monitoring of Endometrial Cancer Recurrence and Progression

    Journal: Cancers

    doi: 10.3390/cancers12082231

    Multiregional sampling from patient 5, alongside the respective variant allele frequencies of the major driver mutation, TP53 p.Y220C, identified in the primary tumor sample (located in the endometrium), local metastatic lesion (located in the ovary) and the distal metastatic lesion (located in the omentum). The levels of cell-free DNA (cfDNA) and ctDNA in pre-treatment and post-treatment plasma samples are shown in the accompanying left-hand graph, clearly demonstrating a rise in ctDNA levels 3 months prior to radiological relapse (right-hand). * samples analyzed exclusively by digital droplet PCR (ddPCR). Grey shaded area indicates treatment with carboplatin and paclitaxel. PR = partial response; RP = radiological progression.
    Figure Legend Snippet: Multiregional sampling from patient 5, alongside the respective variant allele frequencies of the major driver mutation, TP53 p.Y220C, identified in the primary tumor sample (located in the endometrium), local metastatic lesion (located in the ovary) and the distal metastatic lesion (located in the omentum). The levels of cell-free DNA (cfDNA) and ctDNA in pre-treatment and post-treatment plasma samples are shown in the accompanying left-hand graph, clearly demonstrating a rise in ctDNA levels 3 months prior to radiological relapse (right-hand). * samples analyzed exclusively by digital droplet PCR (ddPCR). Grey shaded area indicates treatment with carboplatin and paclitaxel. PR = partial response; RP = radiological progression.

    Techniques Used: Sampling, Variant Assay, Mutagenesis, Polymerase Chain Reaction

    3) Product Images from "Epigenetic Analysis of Circulating Tumor DNA in Localized and Metastatic Prostate Cancer: Evaluation of Clinical Biomarker Potential"

    Article Title: Epigenetic Analysis of Circulating Tumor DNA in Localized and Metastatic Prostate Cancer: Evaluation of Clinical Biomarker Potential

    Journal: Cells

    doi: 10.3390/cells9061362

    Circulating tumor DNA (ctDNA) detection in plasma and matched PCa tissue samples using MS-ddPCR. ( A – C ) Ratio between methylated ctDNA and cfDNA copies for DOCK2 ( A ), HALPN3 ( B ), and FBXO30 ( C ) in plasma samples from healthy controls, BPH, localized PCa (PCa M0), and metastatic PCa patients (PCa M1). Each dot represents one analyzed sample. ( D – F ) Total number of copies of DOCK2 ( D ), HALPN3 ( E ), and FBXO30 ( F ) in BPH/AN tissue samples, and in matched PCa tissue samples and plasma samples from patients with localized PCa. Each dot represents one analyzed sample. ( G – I ) ROC curves comparing 19 BPH/AN and 41 PCa tissue samples for DOCK2 ( G ), HALPN3 ( H ), and FBXO30 methylation ( I ). p -values were calculated using Mann–Whitney tests. Horizontal bars indicate median values in each group. Healthy, healthy controls. BPH, benign prostatic hyperplasia. PCa, prostate cancer. M0, non-metastatic disease. M1, metastatic disease. ROC, receiver operating curve. AUC, area under the curve.
    Figure Legend Snippet: Circulating tumor DNA (ctDNA) detection in plasma and matched PCa tissue samples using MS-ddPCR. ( A – C ) Ratio between methylated ctDNA and cfDNA copies for DOCK2 ( A ), HALPN3 ( B ), and FBXO30 ( C ) in plasma samples from healthy controls, BPH, localized PCa (PCa M0), and metastatic PCa patients (PCa M1). Each dot represents one analyzed sample. ( D – F ) Total number of copies of DOCK2 ( D ), HALPN3 ( E ), and FBXO30 ( F ) in BPH/AN tissue samples, and in matched PCa tissue samples and plasma samples from patients with localized PCa. Each dot represents one analyzed sample. ( G – I ) ROC curves comparing 19 BPH/AN and 41 PCa tissue samples for DOCK2 ( G ), HALPN3 ( H ), and FBXO30 methylation ( I ). p -values were calculated using Mann–Whitney tests. Horizontal bars indicate median values in each group. Healthy, healthy controls. BPH, benign prostatic hyperplasia. PCa, prostate cancer. M0, non-metastatic disease. M1, metastatic disease. ROC, receiver operating curve. AUC, area under the curve.

    Techniques Used: Methylation, MANN-WHITNEY

    Evaluation of biomarker candidates using methylations-specific droplet digital PCR. ( A ) Twelve methylation-specific droplet digital PCR (MS-ddPCR) assays were tested on DNA from peripheral blood cell samples from healthy donors ( n = 44). ( B ) Four MS-ddPCR assays were further tested on cfDNA samples from healthy donors ( n = 16). Each dot represents one analyzed sample. Candidate genes with no signal are marked with Accepted. Median values are indicated with horizontal grey lines. cfDNA, circulating cell-free DNA.
    Figure Legend Snippet: Evaluation of biomarker candidates using methylations-specific droplet digital PCR. ( A ) Twelve methylation-specific droplet digital PCR (MS-ddPCR) assays were tested on DNA from peripheral blood cell samples from healthy donors ( n = 44). ( B ) Four MS-ddPCR assays were further tested on cfDNA samples from healthy donors ( n = 16). Each dot represents one analyzed sample. Candidate genes with no signal are marked with Accepted. Median values are indicated with horizontal grey lines. cfDNA, circulating cell-free DNA.

    Techniques Used: Biomarker Assay, Digital PCR, Methylation

    Related Articles

    Sequencing:

    Article Title: Comparison of commercially available whole-genome sequencing kits for variant detection in circulating cell-free DNA
    Article Snippet: .. Whole-genome sequencing The ThruPLEX Plasma-seq Kit (Rubicon Genomics, Ann Arbor, USA), the QIAseq cfDNA All-in-One kit (Qiagen, Courtaboeuf, France), the NEXTFLEX Cell Free DNA-seq for Illumina kit (Biooscientific, Austin, USA), the Accel-NGS 2 S PCR FREE DNA Library for Illumina kit and the Accel-NGS 2 S PLUS DNA Library for Illumina kit (Swift Biosciences, Ann Arbor, USA) were used. ..

    Formalin-fixed Paraffin-Embedded:

    Article Title: Adaptor Template Oligo-Mediated Sequencing (ATOM-Seq): A versatile and ultra-sensitive UMI-based NGS library preparation technology, for use with cfDNA and cfRNA
    Article Snippet: .. These are all founded on its ability to capture the 3’ ends of any available nucleic acid, including double- and single-strand DNA, enzymatically or sonicated FFPE derived DNA, cfDNA, and single- or double-strand cDNA derived from total RNA (high quality or FFPE), cfRNA or cfDNA+cfRNA from a total cell free nucleic acid extraction. ..

    DNA Sequencing:

    Article Title: Comparison of commercially available whole-genome sequencing kits for variant detection in circulating cell-free DNA
    Article Snippet: .. Whole-genome sequencing The ThruPLEX Plasma-seq Kit (Rubicon Genomics, Ann Arbor, USA), the QIAseq cfDNA All-in-One kit (Qiagen, Courtaboeuf, France), the NEXTFLEX Cell Free DNA-seq for Illumina kit (Biooscientific, Austin, USA), the Accel-NGS 2 S PCR FREE DNA Library for Illumina kit and the Accel-NGS 2 S PLUS DNA Library for Illumina kit (Swift Biosciences, Ann Arbor, USA) were used. ..

    Polymerase Chain Reaction:

    Article Title: Comparison of commercially available whole-genome sequencing kits for variant detection in circulating cell-free DNA
    Article Snippet: .. Whole-genome sequencing The ThruPLEX Plasma-seq Kit (Rubicon Genomics, Ann Arbor, USA), the QIAseq cfDNA All-in-One kit (Qiagen, Courtaboeuf, France), the NEXTFLEX Cell Free DNA-seq for Illumina kit (Biooscientific, Austin, USA), the Accel-NGS 2 S PCR FREE DNA Library for Illumina kit and the Accel-NGS 2 S PLUS DNA Library for Illumina kit (Swift Biosciences, Ann Arbor, USA) were used. ..

    Sonication:

    Article Title: Adaptor Template Oligo-Mediated Sequencing (ATOM-Seq): A versatile and ultra-sensitive UMI-based NGS library preparation technology, for use with cfDNA and cfRNA
    Article Snippet: .. These are all founded on its ability to capture the 3’ ends of any available nucleic acid, including double- and single-strand DNA, enzymatically or sonicated FFPE derived DNA, cfDNA, and single- or double-strand cDNA derived from total RNA (high quality or FFPE), cfRNA or cfDNA+cfRNA from a total cell free nucleic acid extraction. ..

    Derivative Assay:

    Article Title: Adaptor Template Oligo-Mediated Sequencing (ATOM-Seq): A versatile and ultra-sensitive UMI-based NGS library preparation technology, for use with cfDNA and cfRNA
    Article Snippet: .. These are all founded on its ability to capture the 3’ ends of any available nucleic acid, including double- and single-strand DNA, enzymatically or sonicated FFPE derived DNA, cfDNA, and single- or double-strand cDNA derived from total RNA (high quality or FFPE), cfRNA or cfDNA+cfRNA from a total cell free nucleic acid extraction. ..

    Similar Products

  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 89
    Qiagen cfdna extraction
    Multiregional sampling from patient 5, alongside the respective variant allele frequencies of the major driver mutation, TP53 p.Y220C, identified in the primary tumor sample (located in the endometrium), local metastatic lesion (located in the ovary) and the distal metastatic lesion (located in the omentum). The levels of cell-free DNA <t>(cfDNA)</t> and <t>ctDNA</t> in pre-treatment and post-treatment plasma samples are shown in the accompanying left-hand graph, clearly demonstrating a rise in ctDNA levels 3 months prior to radiological relapse (right-hand). * samples analyzed exclusively by digital droplet PCR (ddPCR). Grey shaded area indicates treatment with carboplatin and paclitaxel. PR = partial response; RP = radiological progression.
    Cfdna Extraction, supplied by Qiagen, used in various techniques. Bioz Stars score: 89/100, based on 7 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cfdna extraction/product/Qiagen
    Average 89 stars, based on 7 article reviews
    Price from $9.99 to $1999.99
    cfdna extraction - by Bioz Stars, 2020-09
    89/100 stars
      Buy from Supplier

    Image Search Results


    Multiregional sampling from patient 5, alongside the respective variant allele frequencies of the major driver mutation, TP53 p.Y220C, identified in the primary tumor sample (located in the endometrium), local metastatic lesion (located in the ovary) and the distal metastatic lesion (located in the omentum). The levels of cell-free DNA (cfDNA) and ctDNA in pre-treatment and post-treatment plasma samples are shown in the accompanying left-hand graph, clearly demonstrating a rise in ctDNA levels 3 months prior to radiological relapse (right-hand). * samples analyzed exclusively by digital droplet PCR (ddPCR). Grey shaded area indicates treatment with carboplatin and paclitaxel. PR = partial response; RP = radiological progression.

    Journal: Cancers

    Article Title: Utility of Circulating Tumor DNA for Detection and Monitoring of Endometrial Cancer Recurrence and Progression

    doi: 10.3390/cancers12082231

    Figure Lengend Snippet: Multiregional sampling from patient 5, alongside the respective variant allele frequencies of the major driver mutation, TP53 p.Y220C, identified in the primary tumor sample (located in the endometrium), local metastatic lesion (located in the ovary) and the distal metastatic lesion (located in the omentum). The levels of cell-free DNA (cfDNA) and ctDNA in pre-treatment and post-treatment plasma samples are shown in the accompanying left-hand graph, clearly demonstrating a rise in ctDNA levels 3 months prior to radiological relapse (right-hand). * samples analyzed exclusively by digital droplet PCR (ddPCR). Grey shaded area indicates treatment with carboplatin and paclitaxel. PR = partial response; RP = radiological progression.

    Article Snippet: As with CTCs, numerous methods are available for total cfDNA extraction from both serum and plasma, with studies illustrating that several pre-analytical factors affect yield and downstream analysis post-venepuncture, including the blood tube used, number of centrifugation steps, centrifugal speed, cfDNA extraction method, and ctDNA detection methods [ , , ].

    Techniques: Sampling, Variant Assay, Mutagenesis, Polymerase Chain Reaction

    Circulating tumor DNA (ctDNA) detection in plasma and matched PCa tissue samples using MS-ddPCR. ( A – C ) Ratio between methylated ctDNA and cfDNA copies for DOCK2 ( A ), HALPN3 ( B ), and FBXO30 ( C ) in plasma samples from healthy controls, BPH, localized PCa (PCa M0), and metastatic PCa patients (PCa M1). Each dot represents one analyzed sample. ( D – F ) Total number of copies of DOCK2 ( D ), HALPN3 ( E ), and FBXO30 ( F ) in BPH/AN tissue samples, and in matched PCa tissue samples and plasma samples from patients with localized PCa. Each dot represents one analyzed sample. ( G – I ) ROC curves comparing 19 BPH/AN and 41 PCa tissue samples for DOCK2 ( G ), HALPN3 ( H ), and FBXO30 methylation ( I ). p -values were calculated using Mann–Whitney tests. Horizontal bars indicate median values in each group. Healthy, healthy controls. BPH, benign prostatic hyperplasia. PCa, prostate cancer. M0, non-metastatic disease. M1, metastatic disease. ROC, receiver operating curve. AUC, area under the curve.

    Journal: Cells

    Article Title: Epigenetic Analysis of Circulating Tumor DNA in Localized and Metastatic Prostate Cancer: Evaluation of Clinical Biomarker Potential

    doi: 10.3390/cells9061362

    Figure Lengend Snippet: Circulating tumor DNA (ctDNA) detection in plasma and matched PCa tissue samples using MS-ddPCR. ( A – C ) Ratio between methylated ctDNA and cfDNA copies for DOCK2 ( A ), HALPN3 ( B ), and FBXO30 ( C ) in plasma samples from healthy controls, BPH, localized PCa (PCa M0), and metastatic PCa patients (PCa M1). Each dot represents one analyzed sample. ( D – F ) Total number of copies of DOCK2 ( D ), HALPN3 ( E ), and FBXO30 ( F ) in BPH/AN tissue samples, and in matched PCa tissue samples and plasma samples from patients with localized PCa. Each dot represents one analyzed sample. ( G – I ) ROC curves comparing 19 BPH/AN and 41 PCa tissue samples for DOCK2 ( G ), HALPN3 ( H ), and FBXO30 methylation ( I ). p -values were calculated using Mann–Whitney tests. Horizontal bars indicate median values in each group. Healthy, healthy controls. BPH, benign prostatic hyperplasia. PCa, prostate cancer. M0, non-metastatic disease. M1, metastatic disease. ROC, receiver operating curve. AUC, area under the curve.

    Article Snippet: In brief, a fixed amount of soybean CPP1 DNA fragments was added to each plasma sample prior to cfDNA extraction.

    Techniques: Methylation, MANN-WHITNEY

    Evaluation of biomarker candidates using methylations-specific droplet digital PCR. ( A ) Twelve methylation-specific droplet digital PCR (MS-ddPCR) assays were tested on DNA from peripheral blood cell samples from healthy donors ( n = 44). ( B ) Four MS-ddPCR assays were further tested on cfDNA samples from healthy donors ( n = 16). Each dot represents one analyzed sample. Candidate genes with no signal are marked with Accepted. Median values are indicated with horizontal grey lines. cfDNA, circulating cell-free DNA.

    Journal: Cells

    Article Title: Epigenetic Analysis of Circulating Tumor DNA in Localized and Metastatic Prostate Cancer: Evaluation of Clinical Biomarker Potential

    doi: 10.3390/cells9061362

    Figure Lengend Snippet: Evaluation of biomarker candidates using methylations-specific droplet digital PCR. ( A ) Twelve methylation-specific droplet digital PCR (MS-ddPCR) assays were tested on DNA from peripheral blood cell samples from healthy donors ( n = 44). ( B ) Four MS-ddPCR assays were further tested on cfDNA samples from healthy donors ( n = 16). Each dot represents one analyzed sample. Candidate genes with no signal are marked with Accepted. Median values are indicated with horizontal grey lines. cfDNA, circulating cell-free DNA.

    Article Snippet: In brief, a fixed amount of soybean CPP1 DNA fragments was added to each plasma sample prior to cfDNA extraction.

    Techniques: Biomarker Assay, Digital PCR, Methylation